Founded by a versatile team of biomedical scientists and computer scientists, Ainnocence provides generative AI based small- and large-molecule design systems that dramatically lower the costs and risks of drug discovery — bringing the industry closer to curing some of mankind’s most intractable diseases.
“We want to equip biotechs and pharmas to tackle moonshot cures that have until now been out of reach due to staggering discovery costs and low success rate. Never before have drug discovery teams had a system of such power at their disposal,” said Dr. Lurong Pan, Founder of Ainnocence. “If a science team provides us with just the sequence information of their biological targets, we can screen billions of protein molecules and compounds in just hours, and in many cases completely bypass high-throughput wet-lab experimentation or certain animal studies.”